[Laboratory and clinical studies of cefmenoxime in pediatric infections].

Abstract

The antimicrobial activity of cefmenoxime (CMX) against clinical isolated organisms was measured; CMX was more active than cefotiam and cefazolin against Escherichia coli and Haemophilus influenzae. The serum concentrations of CMX following intravenous injection of 20 mg/kg were 25.6, 10.3, 3.0 micrograms/ml at 30, 60, 120 minutes after injection, respectively. CMX was excreted 60.9% in urine within 6 hours after injection. CMX was administered clinically to 22 pediatric patients with various infections (respiratory tract infection 16 including 1 pyothorax, urinary tract infection 4, tonsillitis with sinusitis 2) at the dose of 39 approximately 96 mg/kg/day for 4 approximately 9 days, and the following satisfactory results were obtained; excellent in 11, good in 9, and poor in 2. The rate of satisfactory clinical response was 90.9%. Eosinophilia 2 cases, slight elevation of transaminase 3 cases, slight elevation of BUN 1 case and transient diarrhea 1 case were observed. But no other serious side effects were observed.

• Authors: Y Miyachi, T Nakashima, K Aso, K Nishikawa, A Ogawa, M Yafuso, K Kuno
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 35 Issue 10 Pg. 2459-67 (Oct 1982) ISSN: 0368-2781 [Print] Japan
• PMID: 6306297 (Publication Type: Journal Article)

Chemical References

• Cefmenoxime
• Cefotaxime

Topics

• Cefmenoxime
• Cefotaxime (analogs & derivatives, metabolism, pharmacology, therapeutic use)
• Child
• Child, Preschool
• Drug Resistance, Microbial
• Enterococcus faecalis (drug effects)
• Female
• Haemophilus influenzae (drug effects)
• Humans
• Infant
• Male
• Respiratory Tract Infections (drug therapy)
• Staphylococcus (drug effects)
• Staphylococcus aureus (drug effects)
• Streptococcus pneumoniae (drug effects)